Remove DNA Remove Genetic Engineering Remove Genome Remove In-Vivo
article thumbnail

Elevating drug discovery through access to in vivo models

Drug Discovery World

At Taconic Biosciences, we are dedicated to advancing drug discovery by providing researchers with straightforward access to the most sophisticated research models engineered to meet the highest genetic, health, and quality standards. This paid-for advertorial by Taconic Biosciences appeared in DDW Volume 25 – Issue 3, Summer 2024.

In-Vivo 59
article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

This week in drug discovery (1-5 July) 

Drug Discovery World

The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant investment and new indications for gene therapies.

article thumbnail

The use of base editing in stem-cell based therapies

Drug Discovery World

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.